DIRECTORS' REPORT

Your Directors have pleasure in presenting the Eighty-second Annual Report and the Audited Financial Statements of the Company for the financial year 2025-26.

Financial Highlights

G in Crores)

Dividend

Your Directors have recommended a final dividend of T 525/- and special dividend of T 131/- per share for the year ended March 31, 2026 on 2,12,49,302 fully paid-up Equity Shares of T 10/- each for approval of the Shareholders at the forthcoming Annual General Meeting (“AGM”). The said dividend, if declared, will absorb a sum of T 1,393.96 Crores.

In terms of the provisions of the Income Tax Act, 2025, dividends paid or distributed by the Company shall be taxable in the hands of the Shareholders. Your Company shall accordingly make the payment of the proposed dividend for the year ended March 31, 2026 after deduction of tax at source.

Dividend Distribution Policy

Dividend Distribution Policy adopted by the Company in terms of requirements under the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time

to time (“SEBI Listing Regulations”) is available on the Company’s website at abbott.co.in/investor-relations. html. The said Policy lays down various factors which are considered by the Board while recommending the dividend for the year.

Material Changes affecting the Company

There have been no material changes and commitments affecting the financial position of the Company between the end of the financial year and date of this report. There has been no change in the nature of business of the Company.

Directors

Ms. Swati Dalal (DIN: 01513751) resigned as Director and Managing Director of the Company with effect from close of business hours on June 13, 2025. Mr. Ambati Venu (DIN: 07614849) and Ms. Alison Davies (DIN: 10658884) resigned as Directors of the Company with effect from close of business hours on December 31, 2025 and April 22, 2026, respectively. Ms. Anisha Motwani (DIN: 06943493) ceased to be Independent Director of the Company with effect from close of business hours on April 24, 2026, upon completion of her second term.

The Board places on record its appreciation for their contribution during their tenure.

The Board of Directors on the recommendation of the Nomination and Remuneration Committee approved the appointment of:

• Mr. Kartik Rajendran (DIN: 09527717), as Director and Managing Director of the Company for a period of 5 (five) years with effect from June 14, 2025, not liable to retire by rotation. The said appointment was approved by the Shareholders at the Eighty-first AGM held on August 13, 2025 and the Central Government on November 21, 2025.

• Mr. Darshan Gada (DIN: 08174581) and Mr. Vivek Mohan (DIN: 00075006) as Non-Executive Directors of the Company with effect from August 18, 2025 and January 1, 2026, respectively, liable to retire by rotation. The said appointments were approved by the Shareholders through Postal Ballot on October 14, 2025 and February 17, 2026, respectively.

• Mr. James Wenner (DIN: 11650998) as Director of the Company with effect from April 23, 2026, liable to retire by rotation and Mr. Neeraj Jain (DIN: 00348591) as Independent Director of the Company for a period of 3 (three) years with effect from April 25, 2026, not

liable to retire by rotation. The said appointments have been proposed for the approval of the Shareholders by way of Postal Ballot.

In accordance with Section 152 of the Companies Act, 2013 (“the Act"):

• Mr. Munir Shaikh (DIN: 00096273), retires by rotation at the ensuing AGM and has not offered himself for re-appointment.

• Mr. Kaiyomarz Marfatia (DIN: 03449627), retires by rotation at the ensuing AGM and being eligible, offers himself for re-appointment.

Declaration of Independence

The Company has received declarations from all the Independent Directors confirming that they meet the criteria of independence prescribed under Section 149(6) of the Act, and the SEBI Listing Regulations and Code for Independent Directors prescribed under Schedule IV to the Act. All the Independent Directors have registered themselves with the Independent Director’s Databank managed by the Indian Institute of Corporate Affairs.

Number of Board Meetings

Seven Board Meetings were held during the financial year 2025-26 on April 18, 2025, May 7, 2025, May 15, 2025, August 12, 2025, November 6, 2025, February 12, 2026 and March 5, 2026. The intervening gap between the Meetings was within the period prescribed under the Act, read with the Secretarial Standards issued by the Institute of Company Secretaries of India on Meetings of the Board of Directors and the SEBI Listing Regulations.

Policy on Nomination and Appointment of Directors/ Criteria for Appointment of Senior Management and Remuneration Policy

The Company has adopted the Policy on Nomination and Appointment of Directors/ Criteria for appointment of Senior Management and Remuneration Policy as per the provisions of Section 178(3) of the Act and the Rules framed thereunder. The said Policies are available on the Company’s website at abbott.co.in/investor-relations.html.

Nomination Policy acts as a guideline for determining qualifications, positive attributes, independence of Directors and matters related to the appointment and removal of Directors and Senior Management.

The Policy lays down:

i. criteria, terms and conditions with regard to identifying suitable candidates who are qualified to become Directors and Senior Management;

ii. appointment mechanism for Managing Director, Executive and Non-Executive Directors, Independent Directors, Key Managerial Personnel and Senior Management;

iii. tenure of Managing Director, Executive Directors and Independent Directors;

iv. their removal process and succession planning.

Remuneration Policy lays down the Company’s philosophy and criteria as well as manner of determining the remuneration of Managing Director, Executive and Non-Executive Directors, Independent Directors, Key Managerial Personnel, Senior Management and other employees.

Performance Evaluation of the Board, Board Committees and Directors

The Company has adopted the Board Evaluation Framework and Policy based on the recommendation of the Nomination and Remuneration Committee, which sets a mechanism and criteria for performance evaluation of the Board,

Board Committees and Directors, including Independent Directors. The same is available at abbott.co.in/investor-relations.html.

Every year, Directors evaluate the effectiveness of the Board and its Committees in performing its governance and oversight responsibilities. Directors assess the performance of their peers, as well as the entire Board of Directors and each of the Committees on which they serve through online questionnaire.

Online Evaluations solicit feedback on various parameters described below:

For Board: Adequacy and timeliness of information provided for reviewing and guiding corporate strategy, risk policy, annual budgets and business plans, setting performance objectives, monitoring financial situation and corporate performance, and overseeing capital expenditures; transparent environment for free-flowing discussion and healthy debate; challenging the assumptions underlying key areas such as strategic initiatives, risk appetite, etc. and provide strategic guidance.

For Committees: Oversight by Committee on respective matters as per Committee Charter, adequacy of information provided and how effectively the recommendations contribute to Board decision-making.

For Directors: Communication of opinions and concerns, anticipation of new issues, leveraging expertise to offer valuable insights and guidance, introduce best industry practices and display adequate level of participation and engagement.

Review and discussions:

• Results are presented in the form of anonymized reports.

• The Nomination and Remuneration Committee reviews the Evaluation Reports.

• Reports are then shared with the Chairman of Board for review and discussions.

Feedback incorporation:

• Based on the feedback, enhancement opportunities are identified and implemented as appropriate.

• The Chairman of the Board discusses peer evaluation results with individual Directors as needed.

During the year 2025-26, evaluation of the Board, Committees and Directors was conducted as per the process described above. Also, the Independent Directors conducted separate assessment of the Board, Non-Independent Directors and the Chairman basis the feedback from the other Board Members.

Key Managerial Personnel

Ms. Swati Dalal (DIN: 01513751) resigned as Director and Managing Director of the Company with effect from June 13, 2025. The Board upon recommendation of the Nomination and Remuneration Committee, approved the appointment of Mr. Kartik Rajendran (DIN: 09527717), as Director and Managing Director of the Company for a period of 5 (five) years with effect from June 14, 2025, not liable to retire by rotation. The said appointment was approved by the Shareholders at the Eighty-first AGM held on August 13, 2025, and the Central Government on November 21, 2025.

The Board upon recommendation of the Audit and Nomination and Remuneration Committees, approved the appointment of Ms. Maithilee Mistry as the Chief Financial Officer of the Company with effect from May 6, 2025.

give a true and fair view of the state of affairs of the Company as at March 31, 2026 and of the Profits of the Company for that year;

c) they have taken proper and sufficient care for the maintenance of adequate accounting records

in accordance with the provisions of the Act, for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities;

d) they have prepared the Annual Accounts of the Company on a going concern basis;

e) they have laid down adequate internal financial controls to be followed by the Company and that such internal financial controls are adequate and operating effectively;

f) they have devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems are adequate and operating effectively.

Related Party Transactions

Policy on Dealing with Related Party Transactions and Materiality

The Company has in place the Policy on dealing with Related Party Transactions and Materiality as per the requirements of the Act and the SEBI Listing Regulations. The said Policy is available on the Company’s website at abbott.co.in/investor-relations.html.

As per the said Policy, all Related Party Transactions are pre-approved by the Independent Directors, Audit Committee and Board, as and when required as per the requirements under the Act and SEBI Listing Regulations. The details of actual transactions are reviewed by the Audit Committee on a quarterly/ annual basis. Material transactions, if any, with the Related Parties are pre-approved by the Shareholders.

Details of Related Party Transactions

The Company enters into business transactions with various Abbott affiliate companies (“Related Parties”) in the normal course of business and at arm’s length.

All the transactions with the Related Parties entered into during the financial year 2025-26 were pre-approved by the Independent Directors and Audit Committee. Actual Transactions are placed before the Audit Committee on a

1. Objective

Risk Management Policy is directed to enable Management to effectively deal with uncertainty and associated risk and opportunity, enhancing the capacity to build value. Broadly, the Policy Framework encompasses:

• Aligning risk appetite and strategy considering the risk appetite in evaluating strategic alternatives, setting related objectives and developing mechanisms to manage related risks;

• Enhancing risk response decisions and select among alternative risk responses - risk avoidance, reduction, sharing and acceptance;

• Reducing operational surprises and losses by identifying potential events and resultant responses, thus reducing surprises and associated costs or losses;

• Identifying and managing multiple and cross enterprise risks;

• Seizing opportunities by considering a full range of potential events and thus identify and proactively realize opportunities;

• Improving deployment of capital through well-established risk information to effectively assess overall capital needs and enhance capital allocation.

These capabilities inherent in this framework help in achieving the performance and profitability targets and prevent loss of resources.

This Risk Management Framework is directed to help ensure effective reporting and compliance with laws and regulations, avoid damage to the Company’s reputation and associated consequences. Risk Management Framework enables the Company to avoid pitfalls and surprises along the way.

Risk involves many variables which are in a state of continuous change. Management in its best effort has tried to design a Risk Management Framework to timely identify major risks for necessary remediation.

2. Roles and Responsibilities Board of Directors

The Board provides oversight about Risk Management and is responsible for approving the Risk Management

Framework. The Board has constituted Risk Management Committee with defined roles and responsibilities.

Audit Committee

Audit Committee conducts evaluation of Risk Management systems, provides oversight of the internal audit function, reviews the scope, findings, and status of corrective actions, and ensures independence and effectiveness of the internal audit process and such other functions as may be assigned by the Board from time to time.

Risk Management Committee

Key roles and responsibilities are outlined below:

i. Monitoring and implementing Risk Management Plans;

ii. Ensures that the adequacy of the Company’s Risk Management Framework is being assessed and that action is taken if it is inadequate;

iii. Reports Risk Management activities and information, including top risks and mitigation, to the Audit Committee and Board;

iv. Understands the significant or high risks affecting Company and ensures that processes to mitigate them are effective;

v. Reviewing and amending Risk Management Framework from time to time;

vi. Such other functions as may be delegated by the Board from time to time.

Risk Management Core Team

The Risk Management Core Team oversees the process by which business division/ function and management identifies and assesses risks and determines appropriate responses. It addresses organizational risks and sets performance, measure goals and key risk indicators for those risks. It takes care of the following:

i. Design, develop and periodically update the Risk Management framework and procedure;

ii. Ensure appropriateness of risk culture and understanding across the Company at all levels;

iii. Plan and organise risk management programs;

iv. Ensure adherence to Risk Management policies and procedures within Abbott;

v. Facilitate validators in preparation and execution of control validation plan;

vi. Conduct adequate awareness;

vii. The Core Team along with the concerned Division/ Function heads identifies risks faced/ perceived by the Company and mitigation plans. The core team further evaluates whether the mitigation measures have helped bring down the scale and magnitude of risk, from time to time.

Statutory Auditors

M/s. Walker Chandiok & Co LLP, Chartered Accountants (Firm Registration No. 001076N/ N500013), have been appointed as Statutory Auditors at the Eightieth AGM of the Company held on August 8, 2024, for a period of five years to hold office till the conclusion of the Eighty-fifth AGM of the Company.

Auditors’ Report

The Auditors’ Report for the financial year 2025-26 does not contain any adverse remarks, qualifications or reservations or disclaimers, which require explanations/ comments by the Board.

Cost Auditors

M/s. Joshi Apte & Associates, Cost Accountants (Firm Registration No. 000240), are the Cost Auditors of the Company for the financial year 2025-26.

M/s. Kishore Bhatia & Associates, Cost Accountants (Firm Registration No. 00294), have been appointed as Cost Auditors of the Company for the financial year 2026-27 at a remuneration of ^ 0.09 Crores plus taxes as applicable and reimbursement of out-of-pocket expenses. The said remuneration to the Cost Auditors shall be subject to ratification by the Members at the ensuing AGM.

Cost Audit Report

As per the provisions of Section 148(1) of the Companies Act, 2013, the Company has maintained the cost records, as specified by the Central Government.

Cost Audit Report along with the Compliance Report for the financial year 2024-25, issued by M/s. Joshi Apte & Associates, Cost Auditors, was filed with the Ministry of Corporate Affairs on August 26, 2025 (due date of filing was September 10, 2025).

Internal Auditors

M/s. Deloitte Touche Tohmatsu India LLP, Chartered Accountants (LLP Identification Number AAE-8458) are the Internal Auditors of the Company. Internal Audit Report, their significant observations and follow-up actions taken by the management are reviewed by the Audit Committee on a quarterly basis.

Secretarial Auditors

M/s. BNP & Associates, Company Secretaries (Firm Registration No. P2014MH037400), have been appointed as Secretarial Auditors of the Company, for a period of five (5) consecutive financial years i.e., from financial year 2025-26 to financial year 2029-30.

Secretarial Audit Report

The Secretarial Audit Report issued by M/s. BNP & Associates, Company Secretaries for the financial year ended March 31, 2026, does not contain any adverse remarks, qualifications, reservations or disclaimer.

Further with reference to the name of the Company appearing in the breach list displayed on the website of Depositories and BSE Limited for having foreign investment in excess of prescribed sectoral cap, the Company received post-facto approval from the Department of Pharmaceuticals permitting foreign shareholding in excess of the sectoral cap, up to 80% of the paid-up share capital of the Company, subject to compounding with the Reserve Bank of India (“RBI”). Accordingly, on filing of the compounding application by the Company, the RBI issued a Compounding Order dated July 31, 2025, whereby a compounding amount of ^2,00,000/- was imposed on the Company. The Company has duly paid the aforesaid compounding amount on August 5, 2025, in line with the directions received from the RBI under the Compounding Order.

Pursuant thereto, the National Securities Depository Limited, on September 30, 2025, removed the Company’s name from its breach list and consequently enhanced the Company’s foreign investment limit to 80%. Accordingly,

the regulatory matter has been conclusively resolved and there are no pending proceedings or further compliances required in this regard.

The Secretarial Audit Report is annexed as “Annexure M” and forms part of this Report.

Reporting of Fraud by Auditors

During the year under review, Statutory Auditors, Cost Auditors, Internal Auditors and Secretarial Auditors have not reported any instances of fraud committed in the Company by its Officers or Employees or reported to the Audit Committee under Section 143(12) of the Act.

Human Resources

At Abbott, we believe that a sustainable future begins with health. Our approach to sustainability is anchored in people - building a workforce that is capable, resilient, and aligned to long-term business priorities. Through our 2030 sustainability agenda, we continue to invest in strengthening workforce capability, leadership depth, and organizational readiness for the future.

Abbott remains an innovative and purpose-driven workplace. Our culture enables employees to contribute meaningfully to improving lives while supporting their own personal and professional growth. This alignment between individual purpose and organizational mission continues to be a key driver of engagement and performance.

Our HR philosophy is closely aligned with the Company’s strategic priorities. We provide differentiated opportunities, benefits, and an enabling environment that allows employees to build sustainable careers while supporting their well-being and that of their families.

Employees continue to be central to the Company’s sustained growth and success. The Company remains focused on building a diverse and future-ready workforce. By fostering diverse perspectives and encouraging innovation, we are strengthening our ability to respond to evolving business needs.

Talent development remains a strategic priority. Our initiatives are designed to enable employee growth, strengthen diversity, equity, and inclusion (DE&I), and build a culture of accountability and ownership. We continue to invest in employee well-being across physical, mental, social, and financial dimensions, while ensuring structured development opportunities across all levels.

Talent Strategy

Our talent strategy is focused on attracting, developing, and retaining high-quality talent while strengthening our position as an employer of choice in the Indian healthcare industry. We drive engagement through shared goals, capability building, and career progression opportunities, supported by a culture of transparency and accountability.

The India Talent Strategy continues to be a key enabler of business outcomes, with strong leadership ownership and execution discipline. Our culture emphasizes ownership, forward thinking, and cultivating a growth mindset - critical drivers of sustained performance.

Training and Capability Building Initiatives

Abbott’s development framework is aligned to business priorities and future capability requirements. Employees are provided access to structured learning interventions that enhance skills, improve role effectiveness, and prepare them for larger responsibilities.

1. Leadership Pipeline Building

Talent Management Reviews (TMR) focus on identifying and developing critical talent across levels. The process strengthens succession pipelines by aligning development actions to key success factors for future roles and ensuring readiness across critical positions.

Transition Programs support employees moving into new roles, particularly from individual contributor to managerial positions. These programs focus on building people leadership capability, decisionmaking ability, and effectiveness in managing team performance.

Structured leadership journeys, including programs such as In-Stride and the Future Leaders Development Program, are designed to accelerate readiness for critical roles. These programs integrate crossfunctional mentoring, structured learning, business simulations, and leadership exposure, enabling participants to operate with broader business perspective.

2. Executive Coaching and Mentoring

Executive coaching continues to be deployed as a focused intervention for senior leaders. These engagements are structured around clearly defined

development objectives and aligned to business priorities. Progress is tracked through milestone achievement and observable shifts in leadership effectiveness.

3. Mentoring Programs

Mentoring initiatives connect senior leaders with employees across the organization to build crossfunctional capability and leadership depth. Structured mentoring frameworks ensure alignment with development needs and business priorities. Focused interventions aimed towards our diverse workforce groups, continue to strengthen leadership pipelines and enable career progression.

4. Managerial Capability Development

The Leading with Impact program continues to strengthen managerial effectiveness across the organization. It combines digital learning, simulations, peer discussions, and coaching to build core leadership capabilities such as empathy, communication, feedback, and team engagement.

The program focuses on enabling managers to translate leadership behaviors into consistent on-ground practice.

5. Training and Development Resources The Abbott Global Training platform provides employees access to role-based learning, instructor-led programs, and digital modules. Customized learning solutions are designed in line with business requirements, ensuring relevance and application

in role.

Career development is further enabled through platforms that provide access to cross-functional opportunities, global exposure, and project-based learning experiences such as Learning Gigs. These interventions support continuous skill development and broader career pathways.

6. Excellence Academy

Excellence Academy continues to strengthen field force capability through structured onboarding and development interventions. The focus remains on improving execution quality, enhancing customer engagement, and enabling consistent performance across markets.

Diversity, Equity and Inclusion (DE&I)

Inclusion is integral to Abbott’s culture and business approach. It is embedded in our values and reflected in how we build teams, develop leaders, and engage with our employees.

We are committed to creating an environment where employees feel valued, respected, and empowered to contribute fully. Our DE&I strategy integrates inclusion into core business processes and supports building teams that reflect the communities we serve.

Our DE&I approach to DE&I is driven through five focus areas: Inclusive Policies and Workplace Practices, Capability and Mindset Development, Hiring Practices, Communication and Awareness, and Forums and Networks.

Inclusive Policies and Workplace Practices

We continue to strengthen policies to ensure fairness and equity across the employee lifecycle. This includes regular reviews of compensation, promotion, and career progression practices to eliminate bias and ensure equitable outcomes.

Capability and Mindset Development

We invest in building inclusive leadership and managerial capability through structured interventions focused on unconscious bias awareness, inclusive leadership behaviors, and cultural competence.

These programs equip managers to lead diverse teams effectively.

Hiring Practices

We continuously strengthen hiring practices to attract and hire from diverse talent pools. Structured processes, standardized assessments, and ongoing monitoring ensure consistency and alignment with our DE&I vision.

Communication and Awareness

Communication and awareness remain critical to driving inclusion. Through campaigns, workshops, and structured learning interventions, we continue to build understanding of inclusion, allyship, and advocacy across the organization.

Forums and Networks

Employee Networks play a key role in strengthening inclusion and engagement by creating platforms for connection, dialogue, and development.

Women Leaders of Abbott: Focuses on enabling women to grow through structured development programs, leadership exposure, and career advancement opportunities.

Working Mothers of Abbott: Provides a platform for working mothers to connect, share experiences, and navigate career and personal responsibilities.

PRIDE Network: Focuses on building awareness and enabling inclusion for LGBTQ employees and allies through structured initiatives across education, policy, and engagement.

Early Career Network: Supports early career professionals through networking, development opportunities, and initiatives such as reverse mentoring to strengthen cross-generational learning.

Abbott disABILITY Network: Focuses on building an inclusive workplace for employees with disabilities by driving awareness, accessibility, and advocacy initiatives.

Technology-Enabled HR and Employee Experience

Abbott continues to leverage technology to improve decision-making, enhance employee experience, and enable consistency across HR processes.

Abbott continues to advance its Talent Acquisition capabilities through targeted technology enablement. Digital hiring journeys have been strengthened through the implementation of high-volume hiring workflows, WhatsApp-based candidate engagement, and end-to-end digitization of offer management. Leveraging CRM platforms such as Phenom, Abbott has enhanced candidate engagement and built scalable talent communities.

Interactive learning platforms such as INcludo provide scenario-based learning experiences that strengthen inclusive hiring practices. These interventions enable managers to identify and mitigate bias, leading to more objective and high-quality talent decisions.

Digital capability-building platforms under Leading with Impact leverage AI-enabled learning to deliver personalized development support. These solutions enhance learning effectiveness through simulations, peer interaction, and coaching integration.

Technology also enables seamless access to Flexible Benefits and wellness programs. We support our employees with an Artificial Intelligence enabled Chatbot “SmaHRty” which is available 24x7 providing real-time employee support, improving responsiveness and overall employee experience.

External Recognition of Efforts

During the year, the Company has been:

• ranked by Avtar & Seramount - 2025 as “100 Best Companies for Women in India” for the 6^th consecutive year, placing Abbott in their “Hall of Fame”.

• recognized as “Exemplars in the Most Inclusive Companies Index” by Avtar & Seramount in 2025,

2^nd time in a row.

• recognized as the “Best Place of Work” at the Business World’s People HR Excellence Awards 2025.

• recognized for “Excellence in Employee Welfare Initiative” at the Business World’s People HR Excellence Awards 2025.

• awarded Platinum Level recognition in the 2025 Healthy Workplace Awards by Arogya World.

• recognized as the most Preferred Workplaces for Women 2025-26 by Marksmen Daily.

• recognized as the most Preferred Workplaces in Healthcare, Pharma & Biotech for 2025-26 by Marksmen Daily.

• conferred the “Maharashtra State Best Employer Brand Award” by World Federation of HR Professionals, endorsed by CHRO Asia.

Prevention of Sexual Harassment (POSH) at Workplace

The Company has complied with the provisions of Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013 and has an Internal Complaints Committee (ICC) in place.

Appropriate training under POSH is imparted to employees regularly.

Summary of the complaints received by the Company/ ICC under the aforesaid Act during the financial year 2025-26 is given below:

Compliance with Maternity Benefit Act, 1961

The Company has complied with the provisions relating to the Maternity Benefit Act, 1961 for the financial year 2025-26.

Health, Safety and Environment

The Company is committed to protecting the health and safety of people and minimizing environmental impact across its operations and value chain. This commitment is embedded in our Environment, Health and Safety (EHS) management systems, governance practices, and day-to-day decision-making.

Advancing our performance in worker safety and environmental stewardship is a long-term priority.

Our efforts build on Abbott’s legacy of responsible operations and are guided by our core values - Pioneering, Achieving, Caring, and Enduring.

Health and Safety

We maintain a structured approach to safety governance, supported by active employee participation. The Goa site has a Safety Committee comprising representatives from both supervisory and non-supervisory employees.

The committee meets regularly to review performance, address risks, and drive continuous improvement.

Capability Building

We invest in strengthening EHS capabilities through continuous learning. Employees participate in on-the-job, classroom, and digital training programs covering:

• Regulatory requirements and internal EHS standards

• Fire prevention and emergency response

• Safe handling of chemicals and waste

• Prevention of slips, trips, and falls

• Machine safety and material handling

We also collaborate with regulatory authorities to enhance technical expertise. During the year:

• An employee from the Goa site completed a four-week certified supervisory program conducted by

the Inspectorate of Factories and Boilers for personnel engaged in hazardous processes. The program combined classroom learning, practical exposure, and project work, with certification awarded upon successful evaluation.

• A two-day Occupational Health and Safety program was conducted at the site in partnership with the Inspectorate of Factories and Boilers, covering key topics such as machine safety, chemical safety, permit-to-work systems, and fire safety.

Strengthening Safety Culture

We continue to build a strong safety culture through engagement and awareness initiatives, including National Safety Week and Abbott EHS Week, which reinforce shared accountability for safe behaviors.

To further embed this culture, we are implementing a Behavior-Based Safety (BBS) program, focused on proactively identifying and addressing unsafe acts.

A structured system for reporting unsafe conditions and near misses supports early risk identification and prevention. Together, these efforts help us maintain a safe workplace, strengthen employee engagement, and drive continuous improvement in EHS performance.

Road Safety

Various Road Safety programs were conducted for field employees during the year:

• 97.64% of the sales employees completed the online defensive riding refresher training module.

• All the new sales employees were trained on defensive riding skills and behaviors.

• 100% of the new sales employees were provided with two helmets (one for self and one for the pillion rider) as a part of the joining kit. In addition to two helmets, they were provided with full finger motorcycle riding gloves, to protect fingers while riding a 2-wheeler vehicle.

To further enhance employee engagement in road safety, Road Safety Week was organized from 10^th - 16^th March 2026. Through the safety week, a series of initiatives like various training programs, quizzes and creative competitions were rolled out with good participation from employees.

Environment

Environmental responsibility is integral to Abbott’s operating philosophy. We are committed to reducing our environmental footprint through responsible resource use and emissions management, while advancing sustainability across our operations.

The site has implemented comprehensive water stewardship practices as part of its commitment to preserving water resources and ensuring long-term availability of quality water. These efforts are designed not only to support operational needs but also to contribute positively to the surrounding community.

In line with the Company’s sustainability objectives, a Membrane Bioreactor (MBR) has been commissioned within the wastewater treatment plant. This advanced biological treatment technology enhances process efficiency and ensures consistent effluent quality, strengthening our approach to responsible water management.

Air emissions from boiler and generator stacks, along with ambient air quality, are monitored on a regular basis and remain well within the limits prescribed by the State Pollution Control Board. The site also promotes circular waste management practices through a vermi-composting unit, which converts canteen food waste into organic manure used for on-site landscaping and plantation.

The site continues to make progress in waste minimization and circularity. Of the total non-hazardous waste generated, 66% is repurposed for beneficial use without requiring recycling, while the remaining 34% is sent for recycling. Hazardous waste is managed through controlled and responsible channels, with 99.35% co-processed in cement industries, ensuring safe disposal with resource recovery. Only a small fraction is incinerated or directed to recycling streams such as used oil and e-waste.

During the year, World Environment Day was observed as part of the Company’s broader EHS awareness initiatives, reinforcing employee engagement and environmental responsibility.

The Goa plant is certified as a Zero Waste to Landfill facility, reflecting our commitment to eliminating landfill disposal and advancing sustainable waste management practices.

Plastic Waste Management

The Company’s operations adhere to the Plastic Waste Management Rules notified by the Ministry of Environment, Forest and Climate Change. The Company maintains compliance with these requirements through established processes designed to ensure responsible collection, processing, and disposal of post-consumer plastic packaging waste.

To support these obligations, the Company has entered into agreements with authorized waste management agencies and Plastic Waste Processors (PWPs) across India.

These arrangements facilitate environmentally sound handling of plastic waste in accordance with applicable regulatory standards.

For the financial year 2025-26, the Company achieved full compliance with its regulatory requirements through the procurement of Plastic Packaging Waste Credits totaling 3,134 MT, representing complete fulfillment of its statutory obligations.

Conservation of Energy, Technology Absorption and Foreign Exchange Earnings and Outgo

The required information under the provisions of Section 134(3)(m) of the Act read with Rule 8 of the Companies (Accounts) Rules, 2014 in respect of Conservation of Energy, Technology Absorption, Foreign Exchange Earnings and Outgo, etc. are annexed as “Annexure MI” and forms part of this Report.

Annual Return

The Annual Return of the Company as on March 31, 2026 has been placed on the website of the Company at abbott.co.in/investor-relations.html.

Disclosure under Section 197(12) of the Companies Act, 2013 and other disclosures as per Rule 5 of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014

Disclosures required in accordance with the provisions of Section 197(12) of the Act, read with Rule 5(1) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 is annexed as “Annexure IV” and forms part of this Report. As per the provisions of Sections 134 and 136 of the Companies Act, 2013, the Report and Financial Statements are being sent to the Members and others entitled thereto, excluding the Statement containing Particulars of Employees, which is available for inspection by the Members up to the date of ensuing Annual General Meeting. Any Member interested in obtaining a copy of such Statement may write to the Company Secretary at investorrelations.india@abbott. com.

Business Responsibility and Sustainability Report (BRSR)

Business Responsibility and Sustainability Report and Independent Assurance Statement on BRSR Core as required under Regulation 34 of the SEBI Listing Regulations forms part of this Report.

Corporate Governance Report

Corporate Governance Report and Certificate issued by Ms. Neena Bhatia, Practicing Company Secretary (Membership No: FCS 9492 and Certificate of Practice No.: 2661) on compliance of the conditions of Corporate Governance as required under Regulation 34 of the SEBI Listing Regulations, form part of this Report.

Compliance with Secretarial Standards

The Board of Directors affirms that the Company has complied with the applicable Secretarial Standards issued by the Institute of Company Secretaries of India (SS1 and SS2) relating to Meetings of Board, its Committees and General Meetings, respectively.

Disclosures of Orders Passed by Regulators or Courts or Tribunal

No orders have been passed by any Regulator or Court or Tribunal which can have impact on the going concern status and the Company’s operations in future.

Industrial Relations

The Company has overall cordial industrial relations.

The Company continues to receive strong support from distributors, suppliers, vendors, stockists and other partners.

Fixed Deposits

No fixed deposits were accepted during the year.

Particulars of Loans, Investments and Guarantees

The Company has not granted any loan or provided any guarantees to or invested in securities of any other body corporate during the year.

General

No disclosure or reporting is required in respect of the following items as there were no transactions relating to these items during the year under review:

1. Issue of equity shares with differential rights as to dividend, voting or otherwise.

2. Issue of shares (including sweat equity shares) to employees of the Company under any scheme.

3. The Company does not have any joint venture or subsidiaries.

4. There are no applications made or any proceeding pending against the Company under Insolvency and Bankruptcy Code, 2016 (31 of 2016) during the financial year.

5. There are no instances of one-time settlement during the financial year.

Acknowledgement

Your Board expresses gratitude towards all the employees, business partners, institutions, banks and the Members, for their continued trust and support to the Company.